Acute pancreatitis associated with boceprevir: a case report

Brazilian Journal of Infectious Diseases

Juliana Miguel Bilar¹  Roberto José Carvalho-filho¹  Carolina Frade Magalhães Girardin Pimentel Mota¹  Patricia Da Silva Fucuta¹  Maria Lucia Cardoso Gomes Ferraz¹ 

关键词: Hepatitis C;    Protease inhibitor;    Side effect;   

DOI  :  10.1016/j.bjid.2014.03.008

来源: SciELO

【 摘 要 】

Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30-50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy, but it is associated with an increased incidence of adverse events. We herein report a case of acute pancreatitis developed during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was the most likely cause of drug-associated pancreatitis after the most common causes were ruled out, since this adverse event had not occurred when the patient had previously been exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of pancreatitis when these two drugs were reintroduced. Acute pancreatitis is a rare adverse event associated with boceprevir therapy, but a potentially fatal event. Sequential determination of pancreatic enzymes should be considered during hepatitis C treatment with boceprevir.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License